Overview

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to compare the pharmacokinetics of a 60 mg dose of cabozantinib in adult subjects with impaired renal function compared with healthy adult subjects. Another objective is to assess the safety and tolerability of cabozantinib in these adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Exelixis